HMS
RVNC

Hanseatic Management Services’s Revance Therapeutics, Inc. RVNC Stock Holding History

Hanseatic Management Services’s Portfolio RVNC Stock Details RVNC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-170
Closed -$4K – 216
2020
Q3 		$4K Buy
170
+59
+53% +$1.55K 0.01% 171
2020
Q2 		$3K Hold
111
– – ﹤0.01% 164
2020
Q1 		$2K Buy
+111
New +$2.3K ﹤0.01% 192

Other funds holding RVNC

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
EWM
Essex Woodlands Management The Woodlands, Texas $251M AUM 13.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Hanseatic Management Services's RVNC Position: Q4 2020 in Review

Hanseatic Management Services sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2020, closing a stake of 170 shares — an estimated $4K sold.

Hanseatic Management Services first reported a position in RVNC in Q1 2020 and held it in 3 quarters. The position peaked at $4K in Q3 2020. 151 funds tracked by Wall St. Rank hold RVNC as of Q4 2020.

  • Hanseatic Management Services reported no remaining Revance Therapeutics, Inc. position as of Q4 2020 after selling out during the quarter.
  • Hanseatic Management Services sold 170 Revance Therapeutics, Inc. shares in Q4 2020, an estimated $4K.
  • Hanseatic Management Services first reported a position in Revance Therapeutics, Inc. in Q1 2020 and held it in 3 quarters.
  • Hanseatic Management Services's Revance Therapeutics, Inc. position peaked at $4K in Q3 2020.
  • 151 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2020.

Based on Hanseatic Management Services's 13F filing for Q4 2020, filed 29 Jan 2021.